Exhaled breath condensate confirming T790M mutation in EGFR-mutated Non-Small Cell Lung Cancer

Exhaled breath condensate confirming T790M mutation in EGFR-mutated Non-Small Cell Lung Cancer

We report a case of metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) sensitizing mutation – deletion exon 19 – treated with first line chemotherapy using Carboplatin and Pemetrexed. The treatment was then changed to first generation tyrosine kinase inhibitor...

Full description

Bibliographic Details
Main Authors:	Caitriona Goggin, Myo Oo Nay, Daniel Ryan, Sinead Toomey, Bryan Hennessy, Paula Calvert
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Series:	Current Problems in Cancer: Case Reports
Subjects:	ctDNA NSCLC EGFR mutation T790M mutation Exhaled Breath Condensate
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666621921000624

Similar Items

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
by: Kana Watanabe, et al.
Published: (2023-08-01)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
by: Gao X, et al.
Published: (2019-11-01)

Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
by: Olivia A. Sagan, et al.
Published: (2023-05-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer
by: HOU Ran, et al.
Published: (2020-06-01)

Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy
by: Martin Filipits, et al.
Published: (2023-07-01)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
by: Yang Chen, et al.
Published: (2018-03-01)

EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits
by: Eszter Bencze, et al.
Published: (2022-10-01)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
by: Hardy Niu, et al.
Published: (2017-09-01)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
by: Akihiro Yoshimura, et al.
Published: (2018-12-01)

Comparative analysis of QS3D versus droplet digital PCR for quantitative measures of EGFR T790M mutation from identical plasma
by: Qiaomei Guo, et al.
Published: (2022-11-01)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
by: Jianxin Chen, et al.
Published: (2022-07-01)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
by: Qiufan Zheng, et al.
Published: (2020-02-01)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
by: John Wen‐Cheng Chang, et al.
Published: (2022-07-01)

Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
by: Yoshiya Matsumoto, et al.
Published: (2022-07-01)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
by: Akihiro Yoshimura, et al.
Published: (2019-03-01)

Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines
by: Jing LI, et al.
Published: (2015-08-01)

Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer
by: Qin YU, et al.
Published: (2017-03-01)

Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
by: Xiaohuang Yang, et al.
Published: (2022-07-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood
by: Shamini Selvarajah, PhD, et al.
Published: (2021-08-01)

Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer
by: Hou D, et al.
Published: (2021-08-01)

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2022-10-01)

Droplet Digital PCR as a Molecular Tool for the Detection of the EGFR T790M Mutation in NSCLC Patients with the EGFR Activating Mutations
by: Durgut S, et al.
Published: (2024-03-01)

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs
by: Zheng Wang, et al.
Published: (2021-05-01)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
by: Tadashi Nishimura, et al.
Published: (2021-04-01)

Next-generation sequencing-based detection in a breast MMPMN patient with EGFR T790M mutation: a rare case report and literature review
by: Huiyun Lv, et al.
Published: (2023-07-01)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
by: Thang Thanh Phan, et al.
Published: (2019-01-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
by: Asao Sakai, et al.
Published: (2013-01-01)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Jason S. Agulnik, et al.
Published: (2022-02-01)

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
by: Xiao-Fang Yi, et al.
Published: (2022-06-01)

Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital
by: Venkata Pradeep Babu Koyyala, et al.
Published: (2018-01-01)

Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
by: Mariella Dono, et al.
Published: (2019-04-01)

A patient with a lung adenosquamous carcinoma harboring a de novo T790M mutation and huge nonbacterial vegetative growths successfully treated with osimertinib: A case report
by: So‐yun Kim, et al.
Published: (2023-06-01)

The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer
by: Wen-Chien Cheng, et al.
Published: (2022-12-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations
by: Huaxin Zhou, et al.
Published: (2022-05-01)